Part I. Epidemiology and public health impact of Alzheimer's disease

2000 ◽  
Vol 46 (10) ◽  
pp. 657-665 ◽  
Author(s):  
David A. Bennett
Keyword(s):  
Public Health ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Health Impact ◽  
Public Health Impact ◽  
Epidemiology And Public Health

scholarly journals The Public Health Impact of Alzheimer's Disease, 2000–2050: Potential Implication of Treatment Advances

2002 ◽  
Vol 23 (1) ◽  
pp. 213-231 ◽  
Author(s):  
Philip D. Sloane ◽  
Sheryl Zimmerman ◽  
Chirayath Suchindran ◽  
Peter Reed ◽  
Lily Wang ◽  
...  
Keyword(s):  
Public Health ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Health Impact ◽  
Public Health Impact ◽  
Potential Implication ◽  
The Public

scholarly journals THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCH

2020 ◽  
pp. 1-2
Author(s):  
A.P. Porsteinsson ◽  
E.D. Clark
Keyword(s):  
Public Health ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Financial Burden ◽  
Public Health Problem ◽  
Symptomatic Treatment ◽  
Health Impact ◽  
Major Public Health Problem ◽  
Medical Needs ◽  
Clinical Benefits

Alzheimer’s disease (AD) remains one of our greatest unmet medical needs, without any approved disease-modifying therapies. The emotional and financial burden of AD is enormous and predicted to grow exponentially with increasing median population age, posing a major public health problem. The potential to prevent or improve cognitive decline due to AD has important implications. There are medications currently approved for symptomatic treatment of AD, but they have limited clinical benefits and do not change the ultimate trajectory of the disease. The need to find effective treatments for AD that can prevent, slow, arrest, or even reverse the disease is ever more urgent and interventions that delay the symptomatic onset of AD would have a major public health impact (1).

Sign in / Sign up

Export Citation Format

Share Document